8:04 ET - Shares of Valeant Pharmaceuticals International jump 12% premarket as the company said it had reduced its debt load faster than expected. Valeant has used divestitures, such as the sale of Sprout Pharmaceuticals announced Monday, and the use of free cash flow to reduce its total debt by $6B since the end of the 1Q 2016. Valeant's long-term debt now stands at $27.14B. Shares are trading around $13.50 each, down from more than $100 in January 2016. (austen.hufford@wsj.com; @austenhufford)

(END) Dow Jones Newswires

November 07, 2017 08:21 ET (13:21 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Valeant Pharma Charts.
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Valeant Pharma Charts.